CGUK20147 / S1931 / Frye
Basic Study Information
Purpose:
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based
drug combination versus a standard of care immunotherapy-based drug combination alone
in treating patients with kidney cancer that has spread to other places in the body
(metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab,
pembrolizumab, and avelumab, may help the body's immune system attack the cancer,
and may interfere with the ability of tumor cells to grow and spread. Axitinib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Surgery to remove the kidney, called a nephrectomy, is also considered standard of
care; however, doctors who treat kidney cancer do not agree on its benefits. It is
not yet known if the addition of surgery to an immunotherapy-based drug combination
works better than an immunotherapy-based drug combination alone in treating patients
with kidney cancer.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Thomas Frye
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search